Low‑Dose Lithium for Mild Cognitive Impairment: What a Pilot Trial Shows About Safety and Feasibility

An early trial of the method involving lithium treatment in people with mild cognitive impairment (MCI) revealed that this strategy was feasible and provided useful information on which further trials could be designed. This is relevant due to the urgent need among healthcare professionals and people suffering from MCI for safe strategies for slowing the disease development and preventing dementia.

Why It Matters

MCI represents an awkward situation in between: there are changes in one’s memory and thinking functions due to which people who suffer from MCI cannot be considered as free from the disease; however, at the same time, their condition does not allow classifying MCI as dementia. It is very difficult emotionally to live with such a diagnosis since most people would like to get some kind of help immediately, and not only years later, when they may already be experiencing serious problems with daily activities.

A pilot study of the use of lithium in this population is important for various reasons other than just being concerned about its efficacy. Lithium is an old drug whose effects in the treatment of mood disorders have been well established in the field of psychiatry. The monitoring needs and side effects associated with the drug are also well-known. If a low dose of the drug is proven to be effective and safe, scientists would have a lot easier time developing a protocol since the drug is already well established.

System-level feasibility results have an impact on future trial design and funding. Showing that patients can be recruited, followed up, and kept in the study lowers the risk of unknowns for sponsors and researchers, which will affect future decisions by regulatory authorities, payers, and the health systems regarding funding priorities. System-level feasibility results are also helpful in calculating how the inclusion of a new drug that needs to be monitored would burden clinicians. This involves integrating the use of a new medication into memory-clinic practices through interdisciplinary cooperation.

Finally, the lithium question highlights a bigger trend in brain health research: combining biological plausibility with practical implementation. Lithium has been studied for potential neuroprotective effects, including pathways involved in cellular resilience and inflammation. None of this is a guarantee of clinical benefit, but it offers a credible rationale for careful trials. The pilot’s biggest contribution is that it moves the conversation from “interesting idea” to “testable plan,” while keeping patient safety at the center.

Who It Affects

Individuals with MCI are the main patients who would benefit from such research. For many of them, the phase of MCI would provide an opportunity to act before their brain function declines significantly. The hope of having a drug solution — albeit one that only slightly delays the decline in brain function — would generate considerable interest among people wanting to do something proactive for their brains. There needs to be clarity on the facts, while ensuring that there is realistic discussion regarding the practicality of taking the drug.

Doctors diagnosing and treating MCI, whether neurologists, geriatricians, psychiatrists, or general practitioners, will require guidelines regarding the appropriateness of considering lithium in this scenario. Feasibility studies, which serve to inform clinical decisions about the usefulness of using the drug, may be available, but they cannot replace the proof of efficacy. In the absence of this proof, doctors will have to make a decision despite potential external pressure to prescribe the drug off-label, taking into account the risks, co-morbidities, other drugs being used, and patient preferences.

Payers and health systems have a vested interest as well. In the event that large-scale studies indicate efficacy, payers face questions around the coverage of this non-patent-protected medication for cognitive function preservation. Prior to establishing effectiveness, the cost implications of the surveillance (tests at a lab and visits to the clinic), possible negative consequences (hospitalization or special consultation), and man-hours come into consideration.

Researchers and trial networks represent yet another key target audience. Conducting a practical pilot study demonstrates that approaches for recruiting participants, ensuring safety, and measuring outcomes are feasible in practice. Consequently, this reduces the entry point into large-scale randomized trials that would be able to test whether or not lithium is a potential treatment for MCI. Moreover, a successful pilot would determine what future investigations should focus on – such as important patient-relevant tests, functional measures, and biomarkers of response.

What Changes

• Trial design and planning: Demonstrated feasibility supports larger randomized studies with longer follow-up and more diverse participants.
• Clinical conversations: Clinicians will need clear guidance to discuss potential risks and unknown benefits if patients ask about off‑label lithium for MCI.
• Monitoring and safety pathways: Health systems should anticipate the need for standardized lab monitoring, dose-management protocols, and cross-specialty coordination if lithium use increases.
• Research priorities: The pilot refocuses attention on repurposing known drugs and on identifying which patients are most likely to benefit.

Practical Implications for practice are obvious. The fact that there was a successful recruitment of people for such a study indicates the feasibility of conducting a more extensive investigation. At the same time, practical barriers to doing so emerge, including patient cooperation and clinic capability. There is also a matter of training doctors who might know little about lithium, if at all, outside the context of psychiatry. In terms of patients, the main lesson to draw from this preliminary experiment is hope but also caution.

Safety considerations will play an important role in making treatment decisions. Lithium possesses a narrow margin of safety when administered in standard dosages, but with regard to the use of low-dose treatments for neuroprotection, the need exists to consider drug interactions and effects on renal health, thyroid activity, and hydration levels, particularly in geriatric populations. Thus, future adoption of such treatments would necessarily include protocols for initial assessment, laboratory monitoring, and criteria for stopping or interrupting treatment altogether. Such factors have ramifications with regard to both workflow and cost, as well as patient eligibility.

Equity and access should be considered at the systemic level. Elderly individuals from marginalized populations may lack adequate representation within clinical trials and encounter difficulties accessing specialized services and regular monitoring. Should lithium emerge as a treatment for neurodegenerative conditions, equitable access would involve conducting clinical trials and delivering medical care in such a way as to minimize transportation problems, cover costs associated with monitoring, and assist family physicians operating in community-based settings.

From a research standpoint, the next steps are clear: larger, well-powered randomized trials with longer follow-up to determine whether lithium changes clinically meaningful outcomes — not just short-term cognitive test scores but everyday function and progression to dementia. Future studies should also explore which subgroups might derive the most benefit, using biomarkers and risk-stratification tools to personalize treatment. Parallel work on safety in older populations, including those with multiple chronic conditions, will be essential.

Policy makers and third-party payers will keep track of these advances. Should there be good evidence, the process to get approval and coverage could be made difficult owing to the fact that the drug is not under patent protection anymore, the requirements for monitoring, and the different levels of ease that providers have with them. Collaboration among scientists, regulatory agencies, and third-party payers will ease the process.

In other words, the pilot trial of lithium in patients with mild cognitive impairment has paved the way for practicality. This is because the findings from this study have shown that this therapeutic intervention can be tested. The future of lithium as an effective intervention in mitigating cognitive decline lies in how well its feasibility can translate into reality through further studies.

Last but not least, it will be important for clinicians to communicate with patients carefully. In doing so, it will be essential to ensure that any message that gets passed to patients does not generate any false hopes; rather, the viability of the strategy should be viewed as a promising logistical step, which may or may not be linked with benefits. Clinicians will have to design messages for patients based on which one would want to take part in research or opt for an off-label approach.

References

1. Gildengers AG, Ibrahim TS, Zeng X, Aizenstein HJ, Alkhateeb SK, Anderson SJ, et al. The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment. Alzheimers Dement (N Y). 2025. https://pubmed.ncbi.nlm.nih.gov/40501510/
2. ClinicalTrials.gov. Lithium As a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) (NCT03185208). ClinicalTrials.gov (U.S. National Library of Medicine). 2025. https://clinicaltrials.gov/study/NCT03185208
3. National Institute on Aging. What Is Mild Cognitive Impairment? NIH National Institute on Aging. 2021. https://www.nia.nih.gov/health/memory-loss-and-forgetfulness/what-mild-cognitive-impairment
4. U.S. Food and Drug Administration. Lithium and Lithium Carbonate: Highlights of Prescribing Information (label). FDA. 2018. https://www.accessdata.fda.gov/drugsatfda\_docs/label/2018/017812s033,018421s032,018558s027lbl.pdf